1. Scrip
  2. >>Business
  3. >>Earnings

Q4 Earnings Preview: Pfizer, Amgen, Allergan, Biogen And Novartis

 
• By Joseph Haas, Jessica Merrill, Eleanor Malone, Mandy Jackson, and Kevin Grogan

Pfizer's fourth-quarter call will be the first with new CEO Albert Bourla, while Amgen will provide reassurances after US Neulasta and Epogen biosimilar launches. Also, concerns swirl around the impending impact of generics on Allergan's blockbuster Restasis, Biogen investors await news on Alzheimer's programs and M&A, and Novartis will face scrutiny of recent launches.

Waiter
What will big pharma dish up in their annual results calls? • Source: Shutterstock

Pfizer Inc.'s fourth quarter earnings call on Jan. 29 will be the first one under the leadership of new CEO Albert Bourla, who took the reigns from Ian Read Jan. 1. Investors will be interested in any signs the drug maker is changing tack, though no big changes are anticipated. Bourla represented Pfizer at the J.P. Morgan Healthcare Conference in January, where he highlighted Read's long track record of success at Pfizer. (Also see "J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges" - Pink Sheet, 8 January, 2019.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.